Capital Midwest Fund

ProNAi Raises $12M Series C Financing To Expand Cancer StudiesThe cancer drug developer ProNAi Therapeutics Inc. Monday announced the closing of a Series C preferred financing round of more than $12 million with existing and new investors.
CytoPherx Raises $34M To Move Into U.S. Clinical TrialsCytoPherx Inc. announced it has completed a $34 million round of funding. The funds will be used to complete United States clinical trials and gain FDA approval to commercialize the CytoPherx anti-inflammatory therapy for acute kidney injury.